Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction

There has been considerable focus on the potential role of nitric oxide (NO) and phosphodiesterase (PDE)-5 inhibition in treating heart failure with preserved ejection fraction (HFpEF). However, the results from studies have been conflicting. In a preclinical study, pre-treatment of diabetic rats wi...

Descripción completa

Detalles Bibliográficos
Autores principales: Cruz, Lucas, Ryan, John J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2017
Materias:
Journal Watch
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034459/
https://www.ncbi.nlm.nih.gov/pubmed/30062153
http://dx.doi.org/10.1016/j.jacbts.2017.05.004
_version_ 1783337886306795520
author Cruz, Lucas
Ryan, John J.
author_facet Cruz, Lucas
Ryan, John J.
author_sort Cruz, Lucas
collection PubMed
description There has been considerable focus on the potential role of nitric oxide (NO) and phosphodiesterase (PDE)-5 inhibition in treating heart failure with preserved ejection fraction (HFpEF). However, the results from studies have been conflicting. In a preclinical study, pre-treatment of diabetic rats with a PDE-5 inhibitor, vardenafil, resulted in a significant decrease in left ventricle stiffness. However, the results from clinical trials have been neutral. In this perspective piece, the authors discuss whether or not it is time to move on from targeting NO and PDE5 for the treatment of HFpEF.
format Online
Article
Text
id pubmed-6034459
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-60344592018-07-30 Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction Cruz, Lucas Ryan, John J. JACC Basic Transl Sci Journal Watch There has been considerable focus on the potential role of nitric oxide (NO) and phosphodiesterase (PDE)-5 inhibition in treating heart failure with preserved ejection fraction (HFpEF). However, the results from studies have been conflicting. In a preclinical study, pre-treatment of diabetic rats with a PDE-5 inhibitor, vardenafil, resulted in a significant decrease in left ventricle stiffness. However, the results from clinical trials have been neutral. In this perspective piece, the authors discuss whether or not it is time to move on from targeting NO and PDE5 for the treatment of HFpEF. Elsevier 2017-06-26 /pmc/articles/PMC6034459/ /pubmed/30062153 http://dx.doi.org/10.1016/j.jacbts.2017.05.004 Text en © 2017 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Journal Watch
Cruz, Lucas
Ryan, John J.
Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction
title Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction
title_full Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction
title_fullStr Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction
title_full_unstemmed Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction
title_short Nitric Oxide Signaling in Heart Failure With Preserved Ejection Fraction
title_sort nitric oxide signaling in heart failure with preserved ejection fraction
topic Journal Watch
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6034459/
https://www.ncbi.nlm.nih.gov/pubmed/30062153
http://dx.doi.org/10.1016/j.jacbts.2017.05.004
work_keys_str_mv AT cruzlucas nitricoxidesignalinginheartfailurewithpreservedejectionfraction
AT ryanjohnj nitricoxidesignalinginheartfailurewithpreservedejectionfraction

Ejemplares similares